{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:50:00Z","timestamp":1762660200343,"version":"build-2065373602"},"reference-count":48,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UK Charity Pancreatic Cancer Research Fund (PCRF; London, UK)","award":["C16420\/A18066"],"award-info":[{"award-number":["C16420\/A18066"]}]},{"name":"BCI CRUK Centre Grant","award":["C16420\/A18066"],"award-info":[{"award-number":["C16420\/A18066"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The prognosis for triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC) is dismal. TNBC and PDAC are highly aggressive cancers with few treatment options and a potential for rapid resistance to standard-of-care chemotherapeutics. Oncolytic adenoviruses (OAds) represent a promising tumour-selective strategy that can overcome treatment resistance and eliminate cancer cells by lysis and host immune activation. We demonstrate that histone deacetylase inhibitors (HDACi) potently enhanced the cancer-cell killing of our OAds, Ad\u2206\u2206 and Ad-3\u2206-A20T in TNBC and PDAC preclinical models. In the TNBC cell lines MDA-MB-436, SUM159 and CAL51, cell killing, viral uptake and replication were increased when treated with sublethal doses of the Class-I-selective HDACis Scriptaid, Romidepsin and MS-275. The pan-HDACi, TSA efficiently improved OAd efficacy, both in vitro and in SUM159 xenograft models in vivo. Cell killing and Ad\u2206\u2206 replication was also significantly increased in five PDAC cell lines when pre-treated with TSA. Efficacy was dependent on treatment time and dose, and on the specific genetic alterations in each cell line. Expression of the cancer specific \u03b1v\u00df6-integrin supported higher viral uptake of the integrin-retargeted Ad-3\u2206-A20T in combination with Scriptaid. In conclusion, we demonstrate that inhibition of specific HDACs is a potential means to enhance OAd activity, supporting clinical translation.<\/jats:p>","DOI":"10.3390\/v14051006","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T23:39:36Z","timestamp":1652225976000},"page":"1006","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad\u2206\u2206 and Ad-3\u2206-A20T in Pancreatic and Triple-Negative Breast Cancer Models"],"prefix":"10.3390","volume":"14","author":[{"given":"Mar\u00eda Del Carmen Rodr\u00edguez","family":"Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-4495","authenticated-orcid":false,"given":"In\u00e9s Garc\u00eda","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"OrganoVIR Labs, Department of Medical Microbiology, Amsterdam Institute for Infection and Immunity, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9326-3632","authenticated-orcid":false,"given":"Callum","family":"Nattress","sequence":"additional","affiliation":[{"name":"Cell Communication Lab, Department of Oncology, University College London Cancer Institute, London WC1E 6DD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahad","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnel","family":"Halld\u00e9n","sequence":"additional","affiliation":[{"name":"Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"ref_1","first-page":"106","article-title":"Current approaches in treatment of triple-negative breast cancer","volume":"12","author":"Wahba","year":"2015","journal-title":"Cancer Biol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00066-020-01680-2","article-title":"R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007\u00b1 trial","volume":"197","author":"Fietkau","year":"2020","journal-title":"Strahlenther. Onkol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ingram, M.A., Lauren, B.N., Pumpalova, Y., Park, J., Lim, F., Bates, S.E., Kastrinos, F., Manji, G.A., Kong, C.Y., and Hur, C. (2022). Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable\/locally advanced pancreatic cancer patients. Cancer Rep., e1565.","DOI":"10.1002\/cnr2.1565"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ctrv.2014.07.003","article-title":"Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside","volume":"40","author":"Oettle","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.omtm.2019.11.001","article-title":"Immunology of Adenoviral Vectors in Cancer Therapy","volume":"15","author":"Shaw","year":"2019","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-09-1960","article-title":"Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers","volume":"16","author":"Yanover","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/gt.2011.141","article-title":"The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models","volume":"18","author":"Cherubini","year":"2011","journal-title":"Gene Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"15703","DOI":"10.18632\/oncotarget.7310","article-title":"The E1B19K-deleted oncolytic adenovirus mutant AdDelta19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11","volume":"7","author":"Pantelidou","year":"2016","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/1535-7163.MCT-17-0671","article-title":"The Novel Oncolytic Adenoviral Mutant Ad5-3Delta-A20T Retargeted to alphavbeta6 Integrins Efficiently Eliminates Pancreatic Cancer Cells","volume":"17","author":"Man","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.1038\/s41598-019-49150-9","article-title":"Systemic delivery and SPECT\/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer","volume":"9","author":"Man","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/1078-0432.CCR-08-2008","article-title":"Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivo","volume":"15","author":"Leitner","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41389-017-0020-8","article-title":"Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad\u2206\u2206 through Bcl-2-dependent attenuation of autophagy","volume":"7","author":"Man","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1089\/hum.2011.218","article-title":"Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5","volume":"23","author":"Coughlan","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cam4.756","article-title":"High expression of integrin beta6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers","volume":"5","author":"Desai","year":"2016","journal-title":"Cancer Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/1078-0432.CCR-13-1504","article-title":"Altered microenvironment promotes progression of preinvasive breast cancer: Myoepithelial expression of alphavbeta6 integrin in DCIS identifies high-risk patients and predicts recurrence","volume":"20","author":"Allen","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e00805-18","DOI":"10.1128\/JVI.00805-18","article-title":"Adenovirus E1A Activation Domain Regulates H3 Acetylation Affecting Varied Steps in Transcription at Different Viral Promoters","volume":"92","author":"Hsu","year":"2018","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1101\/gad.324814.119","article-title":"Dedifferentiation by adenovirus E1A due to inactivation of Hippo pathway effectors YAP and TAZ","volume":"33","author":"Zemke","year":"2019","journal-title":"Genes Dev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.chom.2014.10.004","article-title":"Adenovirus small E1A employs the lysine acetylases p300\/CBP and tumor suppressor Rb to repress select host genes and promote productive virus infection","volume":"16","author":"Ferrari","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1101\/gr.132308.111","article-title":"Reorganization of the host epigenome by a viral oncogene","volume":"22","author":"Ferrari","year":"2012","journal-title":"Genome Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","article-title":"Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/OV.S66081","article-title":"Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy","volume":"4","author":"Chiocca","year":"2015","journal-title":"Oncolytic Virother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jval.2016.01.015","article-title":"Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis","volume":"19","author":"Steuten","year":"2016","journal-title":"Value Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41420-021-00635-5","article-title":"Epigenetic derepression converts PPARgamma into a druggable target in triple-negative and endocrine-resistant breast cancers","volume":"7","author":"Loo","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Eckschlager, T., Plch, J., Stiborova, M., and Hrabeta, J. (2017). Histone Deacetylase Inhibitors as Anticancer Drugs. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071414"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1535-7163.MCT-07-0395","article-title":"Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models","volume":"7","author":"Sasaki","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/1535-7163.MCT-06-0431","article-title":"The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems","volume":"6","author":"Goldsmith","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Berghauser Pont, L.M., Kleijn, A., Kloezeman, J.J., van den Bossche, W., Kaufmann, J.K., de Vrij, J., Leenstra, S., Dirven, C.M., and Lamfers, M.L. (2015). The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127058"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"26328","DOI":"10.18632\/oncotarget.25242","article-title":"Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus","volume":"9","author":"Davies","year":"2018","journal-title":"Oncotarget"},{"key":"ref_30","first-page":"218","article-title":"Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors","volume":"29","author":"Lee","year":"2011","journal-title":"Int. J. Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bbagrm.2010.05.008","article-title":"Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions","volume":"1799","author":"Marks","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_32","first-page":"323","article-title":"A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells","volume":"17","author":"Takai","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"ref_33","first-page":"63","article-title":"Promising oncolytic agents for metastatic breast cancer treatment","volume":"4","author":"Cody","year":"2015","journal-title":"Oncolytic Virother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.07.006","article-title":"Advances in oncolytic adenovirus therapy for pancreatic cancer","volume":"434","author":"Nattress","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e003254","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Laquente","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gao, J., Zhang, W., and Ehrhardt, A. (2020). Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy. Cancers, 12.","DOI":"10.3390\/cancers12051139"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CMR.0b013e328307c248","article-title":"Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma","volume":"18","author":"Hauschild","year":"2008","journal-title":"Melanoma Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2006-05-021873","article-title":"Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias","volume":"109","author":"Gojo","year":"2006","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.cgt.7700726","article-title":"Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells","volume":"11","author":"Sachs","year":"2004","journal-title":"Cancer Gene Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"BSR20180360","DOI":"10.1042\/BSR20180360","article-title":"Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma","volume":"38","author":"Liu","year":"2018","journal-title":"Biosci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"97344","DOI":"10.18632\/oncotarget.22107","article-title":"Combined therapy of colon carcinomas with an oncolytic adenovirus and valproic acid","volume":"8","author":"Bressy","year":"2017","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/emmm.201302796","article-title":"Synergistic combination of valproic acid and oncolytic parvovirus H-1 PV as a potential therapy against cervical and pancreatic carcinomas","volume":"5","author":"Li","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3892\/or_00000417","article-title":"Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231","volume":"22","author":"Kobayashi","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.juro.2006.10.034","article-title":"A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells","volume":"177","author":"Okegawa","year":"2007","journal-title":"J. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.yexcr.2005.10.026","article-title":"Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells","volume":"312","author":"Watanabe","year":"2006","journal-title":"Exp. Cell Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e00088-19","DOI":"10.1128\/JVI.00088-19","article-title":"Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication","volume":"93","author":"Saha","year":"2019","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-14-2993","article-title":"PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is not Associated with Trastuzumab Resistance","volume":"21","author":"Stern","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"872743","DOI":"10.1155\/2013\/872743","article-title":"Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines","volume":"2013","author":"Barnabas","year":"2013","journal-title":"Int. J. Breast Cancer"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/5\/1006\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:08:12Z","timestamp":1760137692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/5\/1006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["v14051006"],"URL":"https:\/\/doi.org\/10.3390\/v14051006","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2022,5,9]]}}}